Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pathlight™ has demonstrated high sensitivity and specificity for early-stage breast cancer MRD detection—100% sensitivity and specificity with a lead time of up to ~13.7 months before clinical recurrence. The technology enables earlier intervention by detecting minimal residual disease at sub-parts-per-million levels in blood. Published data support its use in both solid tumors and hematologic malignancies. The company partners with biopharma for development programs across a range of cancers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SAGA Diagnostics.